Sernova Announces Appointment of Ross Haghighat as Chair of the Board and a Change of Name to Sernova Biotherapeutics

LONDON, Ontario and BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio-hybrid organ as a functional cure for Type 1 diabetes (T1D), today announced the appointment of Ross Haghighat as Chair of the Board. With a proven track record in driving successful innovations, strategic growth and mergers and acquisitions in the biotechnology and life sciences sectors, Mr. Haghig ...